Compare Bristol-Myers Squibb Co (BMY) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs MasterCard Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while MasterCard Inc trades at $539 (market cap $475.39B). The key difference: MasterCard Inc is far larger — about 4.1× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | MA | |
|---|---|---|
Market Cap | $116.30B | $475.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $598.96 |
52-Week Low | $42.60 | $471.55 |
Enterprise Value | $152.24B | $486.13B |
Dividend Yield | 4.42% | 0.65% |
Volume | — | 4,635,698 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Mastercard (MA) trades at $537.70, up 2.08% today, near its pivot point of $537 with bullish moving averages and strong institutional buying interest. The company demonstrates robust fundamentals with 2025 revenue of $32.79B, net income margin of 45.88%, and consistent earnings beats. Recent news highlights AI payment innovations and expanding financial inclusion initiatives, supporting positive sentiment.
Outlook remains favorable given earnings momentum and analyst consensus target of $634.27 (18% upside). Key risks include payment disruption from stablecoins and competitive pressures. High P/E of 31.14 reflects premium valuation, but strong cash flow growth and 79% buy ratings suggest continued institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
